Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Payables (2016 - 2025)

Historic Payables for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $28.3 million.

  • Rocket Pharmaceuticals' Payables fell 2390.06% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 2390.06%. This contributed to the annual value of $37.8 million for FY2024, which is 1738.85% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Payables stood at $28.3 million, which was down 2390.06% from $40.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Payables high stood at $45.8 million for Q4 2023, and its period low was $19.6 million during Q4 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' median Payables value was $30.6 million (recorded in 2023), while the average stood at $30.9 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 10274.19% in 2021, then crashed by 4749.96% in 2022.
  • Rocket Pharmaceuticals' Payables (Quarter) stood at $19.6 million in 2021, then surged by 86.9% to $36.7 million in 2022, then grew by 24.9% to $45.8 million in 2023, then dropped by 17.39% to $37.8 million in 2024, then dropped by 25.3% to $28.3 million in 2025.
  • Its Payables was $28.3 million in Q3 2025, compared to $40.5 million in Q2 2025 and $32.4 million in Q1 2025.